Qiagen QGEN · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
DAX
50.55
+0.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Qiagen
Its shares trade under the ticker QGEN. It has been listed since 1 September 1996. It is a member of the DAX. In the fiscal year to 31 December 2025, it reported revenue of $2.09bn and net income of $424.9m. At that date it held total assets of $6.30bn and shareholders' equity of $3.78bn.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. The company is headquartered in Venlo, Limburg. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 1 Sept 1996
- Employees
- 5,700
- Website
- qiagen.com ↗
- Head office
- HULSTERWEG 82, PL VENLO, 5912 PL
- Incorporated in
- P7
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Stephen RusckowskiIndependent Chairman of the Supervisory Board, since 2023$89,056
- Mr. Thierry BernardChief Executive Officer, Managing Director, Member of the Executive Board, since 2020$2.5m
- Mr. Roland SackersManaging Director, Chief Financial Officer, Member of the Executive Board$1.3m
- Dr. Metin ColpanIndependent Member of the Supervisory Board, since 1985$93,556
- Dr. Toralf HaagIndependent Member of the Supervisory Board$89,556
- Dr. Eva PisaIndependent Member of the Supervisory Board$80,806
- Mr. Mark StevensonIndependent Member of the Supervisory Board
- Ms. Elizabeth TallettIndependent Member of the Supervisory Board$103,306
- Mr. Bert van MeursIndependent Member of the Supervisory Board$51,380
- Ms. Eva van PeltIndependent Member of the Supervisory Board$60,420
- Ms. Domenica MartoranaAssociate Director Global Investor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 99
- Social
- 99
- Governance
- 74
- Direct emissions (scope 1)
- 11,378 t
- Energy emissions (scope 2)
- 14,718 t
- Value chain emissions (scope 3)
- 319,571 t
- Women in the workforce
- 50.78925%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- QIAGEN NV provides Sample to Insight solutions integrating sample and assay technologies for molecular insights.
- QIAGEN employs 5,610 full-time employees in Venlo, Limburg for efficient operations.
- QIAGEN's bioinformatics solutions interpret data to provide actionable molecular insights.
Weaknesses
- QIAGEN's headquarters in Venlo, Limburg may limit access to global innovation hubs.
- QIAGEN's focus on Life Sciences Tools & Services restricts diversification into other sectors.
- QIAGEN's reliance on PCR and NGS technologies could face technological disruption.
Opportunities
- QIAGEN can expand its Sample to Insight solutions in the growing Health Care sector.
- QIAGEN's bioinformatics solutions offer opportunities in genomic data analysis for research.
- QIAGEN's automation platforms based on PCR and NGS can support global molecular testing workflows.
Threats
- QIAGEN faces competition from Life Sciences Tools & Services providers in the Health Care sector.
- QIAGEN's dependence on PCR and NGS technologies may lead to obsolescence from new innovations.
- QIAGEN's operations in Venlo, Limburg could be affected by regional economic downturns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.